Product Pipeline
Enrichment of the Novalar product pipeline is top priority. Patients deserve it. The industry needs it. Through our professional dental partnerships, we are able to develop targeted oral pharmaceutical solutions to enrich the patient experience.
NV-201
In June 2007, Novalar licensed the patent rights for NV-201 from the Boston-based Forsyth Institute. NV-201 utilizes a polymer fiber to locally deliver an antibiotic directly into the root canal for the purpose of reducing the bacteria most often associated with inter-appointment pain. The antibiotic used in NV-201 is clindamycin, an antibiotic commonly used systemically in endodontics.
Published literature has cited a high incidence of root canal failure in necrotic teeth treated in a single visit, attributed to the presence of residual bacteria. It is estimated that the overall success rate of endodontic treatment could be as much as 10-26% (Nagaoka et al.) higher if the root canal is successfully disinfected prior to final restoration.
Novalar believes that there is a significant market opportunity for a novel therapy in treating root canals - with approximately 17 million root canal procedures performed annually in the United States alone. In fact, preliminary market research conducted by Forsyth indicates a demand from endodontists and general dentists for this novel product concept. And as the vast majority of endodontic procedures are conducted by general dentists, NV-201 provides a unique strategic fit with OraVerse™.
Like each inventive Novalar solution, NV-201 and its path through development is guided by a talented team in action with industry expertise in successful clinical development, sales and marketing, and new product launches. By expanding our pipeline with product candidates such as NV-201, Novalar is on its way to becoming a premier oral specialty pharmaceutical company.
